Compare EDIT & UTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | UTMD |
|---|---|---|
| Founded | 2013 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 196.4M |
| IPO Year | 2016 | 1994 |
| Metric | EDIT | UTMD |
|---|---|---|
| Price | $2.66 | $62.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.92 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 10.2K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | $31,937,000.00 | ★ $38,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.14 |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $0.91 | $51.27 |
| 52 Week High | $4.54 | $68.71 |
| Indicator | EDIT | UTMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 47.57 |
| Support Level | $2.42 | $60.56 |
| Resistance Level | $2.76 | $64.21 |
| Average True Range (ATR) | 0.16 | 2.20 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 87.10 | 36.94 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.